$55.39
4.21% today
NYSE, Apr 04, 07:45 pm CET
ISIN
US1101221083
Symbol
BMY
Sector
Industry

Bristol-Myers Squibb Target price 2025 - Analyst rating & recommendation

Bristol-Myers Squibb Classifications & Recommendation:

Buy
27%
Hold
69%
Sell
4%

Bristol-Myers Squibb Price Target

Target Price $60.68
Price $57.82
Potential
Number of Estimates 19
19 Analysts have issued a price target Bristol-Myers Squibb 2026 . The average Bristol-Myers Squibb target price is $60.68. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 26 analysts: 7 Analysts recommend Bristol-Myers Squibb to buy, 18 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Bristol-Myers Squibb stock has an average upside potential 2026 of . Most analysts recommend the Bristol-Myers Squibb stock at Hold.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Billion $ 48.30 45.61
7.32% 5.56%
EBITDA Margin 39.98% 41.63%
1.59% 4.13%
Net Margin -18.53% 24.80%
206.46% 233.87%

22 Analysts have issued a sales forecast Bristol-Myers Squibb 2025 . The average Bristol-Myers Squibb sales estimate is

$45.6b
Unlock
. This is
5.56% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$46.0b 4.69%
Unlock
, the lowest is
$45.2b 6.34%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $48.3b 7.32%
2025
$45.6b 5.56%
Unlock
2026
$43.0b 5.72%
Unlock
2027
$42.8b 0.41%
Unlock
2028
$40.0b 6.57%
Unlock
2029
$38.5b 3.89%
Unlock

12 Analysts have issued an Bristol-Myers Squibb EBITDA forecast 2025. The average Bristol-Myers Squibb EBITDA estimate is

$19.0b
Unlock
. This is
2.71% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$24.9b 34.51%
Unlock
, the lowest is
$17.3b 6.65%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $19.3b 5.61%
2025
$19.0b 1.65%
Unlock
2026
$17.0b 10.68%
Unlock
2027
$16.8b 0.91%
Unlock
2028
$15.9b 5.36%
Unlock
2029
$16.3b 2.59%
Unlock

EBITDA Margin

2024 39.98% 1.59%
2025
41.63% 4.13%
Unlock
2026
39.44% 5.26%
Unlock
2027
39.24% 0.51%
Unlock
2028
39.75% 1.30%
Unlock
2029
42.43% 6.74%
Unlock

11 Bristol-Myers Squibb Analysts have issued a net profit forecast 2025. The average Bristol-Myers Squibb net profit estimate is

$11.3b
Unlock
. This is
225.84% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$14.2b 257.56%
Unlock
, the lowest is
$6.7b 174.04%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-8.9b 214.25%
2025
$11.3b 226.41%
Unlock
2026
$10.4b 7.69%
Unlock
2027
$10.3b 0.92%
Unlock
2028
$9.8b 5.25%
Unlock
2029
$9.8b 0.42%
Unlock

Net Margin

2024 -18.53% 206.46%
2025
24.80% 233.87%
Unlock
2026
24.28% 2.10%
Unlock
2027
24.16% 0.49%
Unlock
2028
24.50% 1.41%
Unlock
2029
25.59% 4.45%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -4.41 5.57
214.25% 226.30%
P/E 10.37
EV/Sales 3.46

11 Analysts have issued a Bristol-Myers Squibb forecast for earnings per share. The average Bristol-Myers Squibb EPS is

$5.57
Unlock
. This is
225.73% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$6.98 257.56%
Unlock
, the lowest is
$3.28 174.04%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-4.41 214.25%
2025
$5.57 226.30%
Unlock
2026
$5.15 7.54%
Unlock
2027
$5.10 0.97%
Unlock
2028
$4.83 5.29%
Unlock
2029
$4.85 0.41%
Unlock

P/E ratio

Current -13.06 192.89%
2025
10.37 179.40%
Unlock
2026
11.24 8.39%
Unlock
2027
11.34 0.89%
Unlock
2028
11.97 5.56%
Unlock
2029
11.92 0.42%
Unlock

Based on analysts' sales estimates for 2025, the Bristol-Myers Squibb stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.27 5.83%
2025
3.46 5.96%
Unlock
2026
3.68 6.06%
Unlock
2027
3.69 0.41%
Unlock
2028
3.95 7.03%
Unlock
2029
4.11 4.05%
Unlock

P/S ratio

Current 2.44 0.03%
2025
2.58 5.89%
Unlock
2026
2.74 6.06%
Unlock
2027
2.75 0.41%
Unlock
2028
2.94 7.03%
Unlock
2029
3.06 4.05%
Unlock

Current Bristol-Myers Squibb Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Wells Fargo
Locked
Locked
Locked Feb 07 2025
Cantor Fitzgerald
Locked
Locked
Locked Feb 04 2025
Citigroup
Locked
Locked
Locked Jan 28 2025
Truist Securities
Locked
Locked
Locked Jan 08 2025
Jefferies
Locked
Locked
Locked Dec 16 2024
B of A Securities
Locked
Locked
Locked Dec 10 2024
Wolfe Research
Locked
Locked
Locked Nov 15 2024
Analyst Rating Date
Locked
Wells Fargo:
Locked
Locked
Feb 07 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Feb 04 2025
Locked
Citigroup:
Locked
Locked
Jan 28 2025
Locked
Truist Securities:
Locked
Locked
Jan 08 2025
Locked
Jefferies:
Locked
Locked
Dec 16 2024
Locked
B of A Securities:
Locked
Locked
Dec 10 2024
Locked
Wolfe Research:
Locked
Locked
Nov 15 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today